All In Vivo Testing articles – Page 2
-
NewsNew study revives long-doubted target for depression drugs
Researchers have shown that changing the molecular structure of NK1 receptor antagonists may restore antidepressant effects after decades of failed trials.
-
NewsRare sugars point to future therapies for alcohol dependence
Researchers have identified a biological pathway linking sugar and appetite for alcohol, suggesting that rare sugars could one day form the basis of new therapies and approaches for reducing alcohol consumption and treating dependence.
-
NewsMaternal stress may alter foetal brain development via immune pathways
Stress during pregnancy may disrupt the maternal gut-immune system, altering foetal brain development and revealing sex-specific vulnerabilities linked to neurodevelopmental risk
-
NewsPropofol and insulin may reduce cognitive decline in older age
New research from the University of Illinois suggests that widely used drugs, including propofol and intranasal insulin, could help protect ageing brains from memory decline and postoperative cognitive impairment.
-
NewsBlocking PAF receptor could offer new liver cirrhosis treatment
Spanish researchers have discovered a key inflammatory mechanism that could lead to new innovative treatments to reduce liver damage and improve vascular function in cirrhosis.
-
NewsEngineered extracellular vesicles control immune responses
Researchers have engineered new extracellular vesicles that can selectively induce antigen-specific regulatory T cells, possibly leading towards safer, more precise treatments for autoimmune and allergic diseases.
-
NewsExperimental drug NU-9 reduces toxic amyloid in early Alzheimer’s
A recently developed experimental drug, called NU-9, has shown promise in targeting a toxic form of amyloid beta – halting Alzheimer’s disease before symptoms appear.
-
NewsUltra-stable hydrogel boosts gastrointestinal wound repair
PolyU researchers have developed a new acid-resistant hydrogel inspired by natural gastric mucus that adheres far better than current treatments.
-
NewsParkinson’s: new study rethinks dopamine’s role in movement
A new study is challenging long-held beliefs about dopamine’s role in movement, revealing new insights into how Parkinson’s disease treatments work and pointing towards more targeted future therapies.
-
NewsBrain drainage repair offers potential new prevention therapies for Alzheimer’s
UVA researchers have discovered a potential treatment approach that restores the brain’s natural drainage system, offering hope for preventing traumatic brain injury-related neurodegeneration.
-
NewsFertility gene PRDM9 linked to relapse in glioblastoma
A study by University of Sydney scientists has discovered why patients with glioblastoma often relapse, identifying a hidden population of cancer cells that hijack a fertility gene to survive chemotherapy.
-
NewsAI-powered CKD drug ISM4808 licensed for kidney disease therapy
Insilico Medicine has partnered with TaiGen Biotechnology to exclusively license its AI-designed PHD inhibitor, ISM4808, for the treatment of CKD-related anaemia in Greater China.
-
NewsNew reverse genetic system accelerates norovirus vaccine research
Researchers at The University of Osaka have developed a new system to study human norovirus, with the hope of being able to develop vaccines and antiviral treatments faster.
-
ArticleLogic-gated DARPins show targeted T-cell activation in tumours
What if a T-cell therapy could activate only inside a tumour? New preclinical data on Molecular Partners’ Switch-DARPin suggest it may do just that.
-
NewsMYC inhibitor Omomyc boosts PARP drug response in breast cancer
A preclinical study led by VHIO reveals that the MYC inhibitor Omomyc enhances the effectiveness of PARP inhibitors, offering a potential new treatment strategy for patients with drug-resistant triple-negative breast cancer.
-
NewsAI powers discovery of new CBLB inhibitor ISM3830
Insilico Medicine has announced ISM3830, an AI-designed CBLB inhibitor that has demonstrated promising preclinical results.
-
NewsRomidepsin drug combo proves effective against resistant childhood cancer
Australian researchers have identified a promising drug combination that can bypass treatment resistance in relapsed neuroblastoma, offering hope in the fight against one of the deadliest childhood cancers.
-
NewsPre-transplant treg therapy reduces GVHD risk for blood cancer patients
Priming the immune system ahead of a stem cell transplant may be key to safer, more effective care for blood cancer patients, according to new research showing major reductions in transplant complications.
-
NewsWhy TIGIT cancer therapies work in monkeys but not humans
A new study reveals that TIGIT, a key immune checkpoint targeted by cancer drugs, behaves differently in rhesus macaques and humans, suggesting current animal tests may be misleading drug development.
-
NewsRhosin shown to reverse blood stem cell ageing
Scientists have discovered that the drug Rhosin can rejuvenate ageing blood stem cells by inhibiting a key protein linked to cellular decline, providing a potential new strategy to combat age-related diseases.